Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...
Chimeric antigen receptor T cell therapy reduces vaccine immunity, with many patients lacking seroprotection despite stable antibody levels.
Researchers are advancing CAR T-cell therapy for solid tumors using armored cells that deliver IL-36γ. Expanded manufacturing ...
80% year-over-year increase in human antibody drug candidates, with the two most advanced now in pivotal Phase 3 trials SAN DIEGO, CA / ACCESS Newswire / March 4, 2026 / Ablexis, LLC, a ...
David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and ...
Monoclonal antibodies (or mAbs) are special proteins made by identical immune cells that all come from the same original cell. These proteins are designed to recognize and attach to specific targets, ...
The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...
Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM). Patients once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results